SCHEMBL3752002

SCHEMBL3752002

COc1ccc(Cl)c(Oc2nc(-c3ccc(C)c(F)c3)ccc2C(=O)O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 6/20 0.44
EIF4E P06730 6/20 0.41
KDM4E B2RXH2 2/20 0.41
PLG P00747 1/20 0.41
PLAU P00749 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
NFKB1 P19838 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
ATM Q13315 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RORC P51449 1/20 0.39
PRKAB2 O43741 1/20 0.39
PRKAG1 P54619 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3749594 0.92 KMO (0.44) KMOEIF4EKDM4EPLGPLAU
SCHEMBL3747338 0.91 SMN1; SMN2 (0.42) KMOKDM4ESMN1; SMN2NPC1ALDH1A1
SCHEMBL3745600 0.85 KMO (0.47) KMOALDH1A1MAPTNPSR1SCN9A
SCHEMBL3339524 0.83 KMO (0.44) KMOEIF4EKDM4EPLGPLAU
SCHEMBL3747199 0.83 SMN1; SMN2 (0.42) KMOKDM4ESMN1; SMN2NPC1ALDH1A1
SCHEMBL3754181 0.80 PLG (0.43) KMOEIF4EKDM4EPLGPLAU
SCHEMBL3749422 0.77 RXFP1 (0.49) KMOSMN1; SMN2
SCHEMBL3759839 0.77 HPGDS (0.42) KMOKDM4EALDH1A1MAPTHPGD
SCHEMBL3345623 0.77 SCN9A (0.41) KMOKDM4EMAPTSCN5ASCN9A
SCHEMBL13054024 0.76 ALDH1A1 (0.43) KMOEIF4ESMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
WO-2008031501-A2 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF NAPRT, PNPO, FABP3 KMO 533/4885EIF4E 3817/4885KDM4E 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.